STOCK TITAN

Vericel Corp - VCEL STOCK NEWS

Welcome to our dedicated news page for Vericel (Ticker: VCEL), a resource for investors and traders seeking the latest updates and insights on Vericel.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Vericel's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Vericel's position in the market.

-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.08%
Tags
management
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.51%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.03%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
26.97%
Tags
conferences
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-23.43%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.16%
Tags
conferences earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.89%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.31%
Tags
conferences
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.25%
Tags
Vericel Corp

Nasdaq:VCEL

VCEL Rankings

VCEL Stock Data

2.32B
44.66M
0.84%
112.24%
9.08%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
US
Cambridge

About VCEL

about vericel founded in 1989, vericel (formerly aastrom biosciences), is dedicated to the development of patient-specific expanded cellular therapies for use in the treatment of patients with severe diseases and conditions. the company markets two cell therapy products in the united states, carticel® (autologous cultured chondrocytes), an autologous chondrocyte implant for the treatment of cartilage defects in the knee and epicel® (cultured epidermal autografts), a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to 30% of total body surface area. vericel is also developing maci, a third-generation autologous chondrocyte implant for the treatment of cartilage defects in the knee, and ixmyelocel-t, a patient specific multicellular therapy for the treatment of advanced heart failure due to ischemic dilated cardiomyopathy (dcm). to fulfill vericel’s mission of helping people with severe diseases and conditions rea